Evergreen Capital Management LLC Has $3.32 Million Holdings in AstraZeneca PLC $AZN

Evergreen Capital Management LLC raised its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 29.4% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 43,319 shares of the company’s stock after acquiring an additional 9,847 shares during the period. Evergreen Capital Management LLC’s holdings in AstraZeneca were worth $3,323,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. NewSquare Capital LLC increased its holdings in AstraZeneca by 149.3% during the 2nd quarter. NewSquare Capital LLC now owns 364 shares of the company’s stock valued at $25,000 after purchasing an additional 218 shares in the last quarter. Richardson Financial Services Inc. increased its stake in shares of AstraZeneca by 59.8% in the second quarter. Richardson Financial Services Inc. now owns 398 shares of the company’s stock valued at $28,000 after buying an additional 149 shares in the last quarter. FSA Wealth Management LLC raised its holdings in shares of AstraZeneca by 376.0% in the second quarter. FSA Wealth Management LLC now owns 476 shares of the company’s stock valued at $33,000 after buying an additional 376 shares during the last quarter. VSM Wealth Advisory LLC acquired a new position in AstraZeneca during the 2nd quarter worth about $33,000. Finally, Maseco LLP bought a new stake in AstraZeneca during the 2nd quarter worth about $34,000. 20.35% of the stock is owned by institutional investors and hedge funds.

AstraZeneca Stock Up 0.4%

NASDAQ:AZN opened at $94.39 on Friday. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $96.51. The stock’s fifty day simple moving average is $91.52 and its 200-day simple moving average is $82.83. The firm has a market capitalization of $292.78 billion, a P/E ratio of 31.36, a P/E/G ratio of 1.56 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.05. The firm had revenue of $15.19 billion for the quarter, compared to analysts’ expectations of $14.75 billion. AstraZeneca had a return on equity of 32.89% and a net margin of 16.17%.The company’s revenue was up 12.0% compared to the same quarter last year. During the same quarter last year, the business earned $2.08 earnings per share. Equities research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

AZN has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of AstraZeneca from a “strong-buy” rating to a “buy” rating in a research note on Saturday. HSBC restated a “buy” rating and issued a $108.00 price objective on shares of AstraZeneca in a research report on Wednesday, December 10th. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research report on Tuesday, January 6th. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a research report on Friday. Finally, Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $95.75.

AstraZeneca Company Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.